---
title: "Sutro Biopharma | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 9.839 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295656306.md"
datetime: "2026-08-12T11:21:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295656306.md)
  - [en](https://longbridge.com/en/news/295656306.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295656306.md)
generator: "portal-rs"
---

# Sutro Biopharma | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 9.839 M

Revenue: As of FY2026 Q2, the actual value is USD 9.839 M, missing the estimate of USD 11.04 M.

EPS: As of FY2026 Q2, the actual value is USD -2.33.

EBIT: As of FY2026 Q2, the actual value is USD -28.17 M.

### Financial Highlights (Second Quarter 2026)

#### Cash, Cash Equivalents and Marketable Securities

Sutro Biopharma, Inc. reported cash, cash equivalents, and marketable securities of $164.3 million as of June 30, 2026, a decrease from $202.6 million as of March 31, 2026. On the balance sheet, cash, cash equivalents and marketable securities were $164,346 thousand as of June 30, 2026, compared to $141,428 thousand as of December 31, 2025.

#### Revenue

Revenue for the quarter ended June 30, 2026, was $9.8 million, a decrease from $63.7 million for the quarter ended June 30, 2025. The 2026 amount was principally related to the Astellas collaboration.

#### Operating Expenses

Total operating expenses for the quarter ended June 30, 2026, were $39,727 thousand, down from $67,090 thousand for the same period in 2025. Research and development (R&D) expenses were $31,695 thousand for Q2 2026, compared to $38,325 thousand for Q2 2025. General and administrative (G&A) expenses were $7,831 thousand for Q2 2026, compared to $10,343 thousand for Q2 2025. Restructuring and related costs were $201 thousand for Q2 2026, significantly lower than $18,422 thousand for Q2 2025.

#### Loss from Operations

Loss from operations increased to - $29,888 thousand for the quarter ended June 30, 2026, from - $3,345 thousand for the quarter ended June 30, 2025.

#### Net Loss

Net loss for the quarter ended June 30, 2026, was - $38,533 thousand, compared to - $11,499 thousand for the quarter ended June 30, 2025.

#### Other Financial Data

-   Interest income was $1,723 thousand for Q2 2026, compared to $2,519 thousand for Q2 2025.
-   Non-cash interest expense related to the sale of future royalties was - $9,862 thousand for Q2 2026, compared to - $9,647 thousand for Q2 2025.
-   Interest and other income (expense), net, was - $505 thousand for Q2 2026, compared to - $1,044 thousand for Q2 2025.
-   Loss before provision for income taxes was - $38,532 thousand for Q2 2026, compared to - $11,517 thousand for Q2 2025.
-   Provision for income taxes was $1 thousand for Q2 2026, compared to - $18 thousand for Q2 2025.
-   Total stockholders’ deficit was - $103,317 thousand as of June 30, 2026, an improvement from - $132,452 thousand as of December 31, 2025.

### Operational Highlights

Sutro Biopharma, Inc. reported encouraging early clinical activity for its STRO-004 Phase 1 study, with dose escalation continuing and multiple responses observed across various cancers. The company received a $10 million milestone payment in April 2026 from its Astellas collaboration, with two R&D programs progressing.

### Outlook / Guidance

Sutro Biopharma, Inc. expects its cash, cash equivalents, and marketable securities of $164.3 million as of June 30, 2026, to fund operations into at least the second quarter of 2028. The company plans to initiate expansion cohorts for the STRO-004 study and provide a data update in the first half of 2027. Additionally, Sutro Biopharma, Inc. anticipates initiating a Phase 1 clinical trial for STRO-006 in the third quarter of 2026 and submitting an IND for STRO-227 in 2026, with a second partnered iADC program expected to enter the clinic in the second half of 2026.

### Related Stocks

- [STRO.US](https://longbridge.com/en/quote/STRO.US.md)

## Related News & Research

- [Northann amends 8-K to file former auditor LAO Professionals’ letter on resignation](https://longbridge.com/en/news/296825824.md)
- [Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split](https://longbridge.com/en/news/296471274.md)
- [Copart amends 8-K to disclose Jane Pocock president compensation package](https://longbridge.com/en/news/296397117.md)
- [Valion Bio amends 8-K to report final vote tally on reverse stock split approval](https://longbridge.com/en/news/296531983.md)
- [Getty Realty amends 8-K to detail Eugene Shnayderman separation, including $300,000 cash payment](https://longbridge.com/en/news/296534890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**